Telomere-driven diseases and telomere-targeting therapies

Journal of Cell Biology

Volumn 216, Issue 4, 2017, Pages 875-887

  Martínez, Paula ^a   Blasco, Maria A ^a  

^a Structural Biology and Biocomputing Programme   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

SHELTERIN; TELOMERASE; UNCLASSIFIED DRUG;

AGING; APLASTIC ANEMIA; CANCER GROWTH; CARCINOGENESIS; DRUG TARGETING; DYSKERATOSIS CONGENITA; HOYERAAL HREIDARSSON SYNDROME; HUMAN; LIVER FIBROSIS; LUNG FIBROSIS; MALIGNANT TRANSFORMATION; MOUSE MODEL; NONHUMAN; PRECLINICAL STUDY; PRIORITY JOURNAL; REVIEW; TELOMERE; TELOMERE HOMEOSTASIS; TELOMERE SHORTENING; ANIMAL; CELL TRANSFORMATION; CHROMOSOMAL INSTABILITY; GENETICS; INTELLECTUAL IMPAIRMENT; INTRAUTERINE GROWTH RETARDATION; MICROCEPHALY; MOLECULARLY TARGETED THERAPY; MUTATION; NEOPLASM; PROCEDURES;

AGING; ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; CHROMOSOMAL INSTABILITY; DYSKERATOSIS CONGENITA; FETAL GROWTH RETARDATION; HUMANS; INTELLECTUAL DISABILITY; MICROCEPHALY; MOLECULAR TARGETED THERAPY; MUTATION; NEOPLASMS; TELOMERASE; TELOMERE; TELOMERE HOMEOSTASIS; TELOMERE SHORTENING;

EID: 85021850744     PISSN: 00219525     EISSN: 15408140     Source Type: Journal    
DOI: 10.1083/jcb.201610111     Document Type: Review

References (143)

1. Agrawal, A., S. Dang, and R. Gabrani. 2012. Recent patents on anti-telomerase cancer therapy. Recent Patents Anticancer. Drug Discov. 7:102-117. http://dx.doi.org/10.2174/157489212798357958
2. Akbay, E.A., C.G. Peña, D. Ruder, J.A. Michel, Y. Nakada, S. Pathak, A.S. Multani, S. Chang, and D.H. Castrillon. 2013. Cooperation between p53 and the telomere-protecting shelterin component Pot1a in endometrial carcinogenesis. Oncogene. 32:2211-2219. http://dx.doi.org/10.1038/onc.2012.232
3. Alder, J.K., J.J. Chen, L. Lancaster, S. Danoff, S.C. Su, J.D. Cogan, I. Vulto, M. Xie, X. Qi, R.M. Tuder, et al. 2008. Short telomeres are a risk factor for idiopathic pulmonary fibrosis. Proc. Natl. Acad. Sci. USA. 105:13051-13056. http://dx.doi.org/10.1073/pnas.0804280105
4. Alder, J.K., N. Guo, F. Kembou, E.M. Parry, C.J. Anderson, A.I. Gorgy, M.F. Walsh, T. Sussan, S. Biswal, W. Mitzner, et al. 2011. Telomere length is a determinant of emphysema susceptibility. Am. J. Respir. Crit. Care Med. 184:904-912. http://dx.doi.org/10.1164/rccm.201103-0520OC
5. Alder, J.K., C.E. Barkauskas, N. Limjunyawong, S.E. Stanley, F. Kembou, R.M. Tuder, B.L. Hogan, W. Mitzner, and M. Armanios. 2015. Telomere dysfunction causes alveolar stem cell failure. Proc. Natl. Acad. Sci. USA. 112:5099-5104. http://dx.doi.org/10.1073/pnas.1504780112
6. Alder, J.K., S.E. Stanley, C.L. Wagner, M. Hamilton, V.S. Hanumanthu, and M. Armanios. 2015. Exome sequencing identifies mutant TINF2 in a family with pulmonary fibrosis. Chest. 147:1361-1368. http://dx.doi.org/10.1378/chest.14-1947
7. Allory, Y., W. Beukers, A. Sagrera, M. Flández, M. Marqués, M. Márquez, K.A. van der Keur, L. Dyrskjot, I. Lurkin, M. Vermeij, et al. 2014. Telomerase reverse transcriptase promoter mutations in bladder cancer: high frequency across stages, detection in urine, and lack of association with outcome. Eur. Urol. 65:360-366. http://dx.doi.org/10.1016/j.eururo.2013.08.052
8. Alter, B.P., P.S. Rosenberg, N. Giri, G.M. Baerlocher, P.M. Lansdorp, and S.A. Savage. 2012. Telomere length is associated with disease severity and declines with age in dyskeratosis congenita. Haematologica. 97:353-359. http://dx.doi.org/10.3324/haematol.2011.055269
9. Aoude, L.G., A.L. Pritchard, C.D. Robles-Espinoza, K. Wadt, M. Harland, J. Choi, M. Gartside, V. Quesada, P. Johansson, J.M. Palmer, et al. 2014. Nonsense mutations in the shelterin complex genes ACD and TERF2IP in familial melanoma. J. Natl. Cancer Inst. 107:dju408. http://dx.doi.org/10.1093/jnci/dju408
10. Armanios, M., and E.H. Blackburn. 2012. The telomere syndromes. Nat. Rev. Genet. 13:693-704. http://dx.doi.org/10.1038/nrg3246
11. Armanios, M.Y., J.J. Chen, J.D. Cogan, J.K. Alder, R.G. Ingersoll, C. Markin, W.E. Lawson, M. Xie, I. Vulto, J.A. Phillips III, et al. 2007. Telomerase mutations in families with idiopathic pulmonary fibrosis. N. Engl. J. Med. 356:1317-1326. http://dx.doi.org/10.1056/NEJMoa066157
12. Artandi, S.E., and R.A. DePinho. 2010. Telomeres and telomerase in cancer. Carcinogenesis. 31:9-18. http://dx.doi.org/10.1093/carcin/bgp268
13. Baerlocher, G.M., E. Oppliger Leibundgut, O.G. Ottmann, G. Spitzer, O. Odenike, M.A. McDevitt, A. Röth, M. Daskalakis, B. Burington, M. Stuart, and D.S. Snyder. 2015. Telomerase inhibitor imetelstat in patients with essential thrombocythemia. N. Engl. J. Med. 373:920-928. http://dx.doi.org/10.1056/NEJMoa1503479
14. Bainbridge, M.N., G.N. Armstrong, M.M. Gramatges, A.A. Bertuch, S.N. Jhangiani, H. Doddapaneni, L. Lewis, J. Tombrello, S. Tsavachidis, Y. Liu, et al. Gliogene Consortium. 2014. Germline mutations in shelterin complex genes are associated with familial glioma. J. Natl. Cancer Inst. 107:dju384. http://dx.doi.org/10.1093/jnci/dju384
15. Ballew, B.J., and S.A. Savage. 2013. Updates on the biology and management of dyskeratosis congenita and related telomere biology disorders. Expert Rev. Hematol. 6:327-337. http://dx.doi.org/10.1586/ehm.13.23
16. Bär, C., and M.A. Blasco. 2016. Telomeres and telomerase as therapeutic targets to prevent and treat age-related diseases. F1000 Res. 5:89
17. Bär, C., B. Bernardes de Jesus, R. Serrano, A. Tejera, E. Ayuso, V. Jimenez, I. Formentini, M. Bobadilla, J. Mizrahi, A. de Martino, et al. 2014. Telomerase expression confers cardioprotection in the adult mouse heart after acute myocardial infarction. Nat. Commun. 5:5863. http://dx.doi.org/10.1038/ncomms6863
18. Bär, C., N. Huber, F. Beier, and M.A. Blasco. 2015. Therapeutic effect of androgen therapy in a mouse model of aplastic anemia produced by short telomeres. Haematologica. 100:1267-1274. http://dx.doi.org/10.3324/haematol.2015.129239
19. Bär, C., J.M. Povedano, R. Serrano, C. Benitez-Buelga, M. Popkes, I. Formentini, M. Bobadilla, F. Bosch, and M.A. Blasco. 2016. Telomerase gene therapy rescues telomere length, bone marrow aplasia, and survival in mice with aplastic anemia. Blood. 127:1770-1779. http://dx.doi.org/10.1182/blood-2015-08-667485
20. Beier, F., M. Foronda, P. Martinez, and M.A. Blasco. 2012. Conditional TRF1 knockout in the hematopoietic compartment leads to bone marrow failure and recapitulates clinical features of dyskeratosis congenita. Blood. 120:2990-3000. http://dx.doi.org/10.1182/blood-2012-03-418038
21. Bernardes de Jesus, B., K. Schneeberger, E. Vera, A. Tejera, C.B. Harley, and M.A. Blasco. 2011. The telomerase activator TA-65 elongates short telomeres and increases health span of adult/old mice without increasing cancer incidence. Aging Cell. 10:604-621. http://dx.doi.org/10.1111/j.1474-9726.2011.00700.x
22. Bernardes de Jesus, B., E. Vera, K. Schneeberger, A.M. Tejera, E. Ayuso, F. Bosch, and M.A. Blasco. 2012. Telomerase gene therapy in adult and old mice delays aging and increases longevity without increasing cancer. EMBO Mol. Med. 4:691-704. http://dx.doi.org/10.1002/emmm.201200245
23. Biroccio, A., J. Cherfils-Vicini, A. Augereau, S. Pinte, S. Bauwens, J. Ye, T. Simonet, B. Horard, K. Jamet, L. Cervera, et al. 2013. TRF2 inhibits a cell-extrinsic pathway through which natural killer cells eliminate cancer cells. Nat. Cell Biol. 15:818-828. http://dx.doi.org/10.1038/ncb2774
24. Blasco, M.A. 2005. Telomeres and human disease: Ageing, cancer and beyond. Nat. Rev. Genet. 6:611-622. http://dx.doi.org/10.1038/nrg1656
25. Blasco, M.A., H.W. Lee, M.P. Hande, E. Samper, P.M. Lansdorp, R.A. DePinho, and C.W. Greider. 1997. Telomere shortening and tumor formation by mouse cells lacking telomerase RNA. Cell. 91:25-34. http://dx.doi.org/10.1016/S0092-8674(01)80006-4
26. Boué, S., I. Paramonov, M.J. Barrero, and J.C. Izpisúa Belmonte. 2010. Analysis of human and mouse reprogramming of somatic cells to induced pluripotent stem cells. What is in the plate? PLoS One. 5:e12664. http://dx.doi.org/10.1371/journal.pone.0012664
27. Buseman, C.M., W.E. Wright, and J.W. Shay. 2012. Is telomerase a viable target in cancer? Mutat. Res. 730:90-97. http://dx.doi.org/10.1016/j.mrfmmm.2011.07.006
28. Calado, R.T., J.A. Regal, D.E. Kleiner, D.S. Schrump, N.R. Peterson, V. Pons, S.J. Chanock, P.M. Lansdorp, and N.S. Young. 2009. A spectrum of severe familial liver disorders associate with telomerase mutations. PLoS One. 4:e7926. http://dx.doi.org/10.1371/journal.pone.0007926
29. Calado, R.T., W.T. Yewdell, K.L. Wilkerson, J.A. Regal, S. Kajigaya, C.A. Stratakis, and N.S. Young. 2009. Sex hormones, acting on the TERT gene, increase telomerase activity in human primary hematopoietic cells. Blood. 114:2236-2243. http://dx.doi.org/10.1182/blood-2008-09-178871
30. Calvete, O., P. Martinez, P. Garcia-Pavia, C. Benitez-Buelga, B. Paumard-Hernández, V. Fernandez, F. Dominguez, C. Salas, N. Romero-Laorden, J. Garcia-Donas, et al. 2015. A mutation in the POT1 gene is responsible for cardiac angiosarcoma in TP53-negative Li-Fraumeni-like families. Nat. Commun. 6:8383. http://dx.doi.org/10.1038/ncomms9383
31. Cawthon, R.M., K.R. Smith, E. O'Brien, A. Sivatchenko, and R.A. Kerber. 2003. Association between telomere length in blood and mortality in people aged 60 years or older. Lancet. 361:393-395. http://dx.doi.org/10.1016/S0140-6736(03)12384-7
32. Cesare, A.J., and J. Karlseder. 2012. A three-state model of telomere control over human proliferative boundaries. Curr. Opin. Cell Biol. 24:731-738. http://dx.doi.org/10.1016/j.ceb.2012.08.007
33. Cesare, A.J., Z. Kaul, S.B. Cohen, C.E. Napier, H.A. Pickett, A.A. Neumann, and R.R. Reddel. 2009. Spontaneous occurrence of telomeric DNA damage response in the absence of chromosome fusions. Nat. Struct. Mol. Biol. 16:1244-1251. http://dx.doi.org/10.1038/nsmb.1725
34. Cesare, A.J., M.T. Hayashi, L. Crabbe, and J. Karlseder. 2013. The telomere deprotection response is functionally distinct from the genomic DNA damage response. Mol. Cell. 51:141-155. http://dx.doi.org/10.1016/j.molcel.2013.06.006
35. Chan, A.K., Y. Yao, Z. Zhang, N.Y. Chung, J.S. Liu, K.K. Li, Z. Shi, D.T. Chan, W.S. Poon, L. Zhou, and H.K. Ng. 2015. TERT promoter mutations contribute to subset prognostication of lower-grade gliomas. Mod. Pathol. 28:177-186. http://dx.doi.org/10.1038/modpathol.2014.94
36. Chin, L., S.E. Artandi, Q. Shen, A. Tam, S.L. Lee, G.J. Gottlieb, C.W. Greider, and R.A. DePinho. 1999. p53 deficiency rescues the adverse effects of telomere loss and cooperates with telomere dysfunction to accelerate carcinogenesis. Cell. 97:527-538. http://dx.doi.org/10.1016/S0092-8674(00)80762-X
37. Cogan, J.D., J.A. Kropski, M. Zhao, D.B. Mitchell, L. Rives, C. Markin, E.T. Garnett, K.H. Montgomery, W.R. Mason, D.F. McKean, et al. 2015. Rare variants in RTEL1 are associated with familial interstitial pneumonia. Am. J. Respir. Crit. Care Med. 191:646-655. http://dx.doi.org/10.1164/rccm.201408-1510OC
38. Collado, M., M.A. Blasco, and M. Serrano. 2007. Cellular senescence in cancer and aging. Cell. 130:223-233. http://dx.doi.org/10.1016/j.cell.2007.07.003
39. Davoli, T., and T. de Lange. 2011. The causes and consequences of polyploidy in normal development and cancer. Annu. Rev. Cell Dev. Biol. 27:585-610. http://dx.doi.org/10.1146/annurev-cellbio-092910-154234
40. Davoli, T., and T. de Lange. 2012. Telomere-driven tetraploidization occurs in human cells undergoing crisis and promotes transformation of mouse cells. Cancer Cell. 21:765-776. http://dx.doi.org/10.1016/j.ccr.2012.03.044
41. de Lange, T. 2005. Shelterin: The protein complex that shapes and safeguards human telomeres. Genes Dev. 19:2100-2110. http://dx.doi.org/10.1101/gad.1346005
42. Diehl, M.C., M.O. Idowu, K.N. Kimmelshue, T.P. York, C.K. Jackson-Cook, K.C. Turner, S.E. Holt, and L.W. Elmore. 2011. Elevated TRF2 in advanced breast cancers with short telomeres. Breast Cancer Res. Treat. 127:623-630. http://dx.doi.org/10.1007/s10549-010-0988-7
43. Di Maro, S., P. Zizza, E. Salvati, V. De Luca, C. Capasso, I. Fotticchia, B. Pagano, L. Marinelli, E. Gilson, E. Novellino, et al. 2014. Shading the TRF2. recruiting function: A new horizon in drug development. J. Am. Chem. Soc. 136:16708-16711. http://dx.doi.org/10.1021/ja5080773
44. Doksani, Y., J.Y. Wu, T. de Lange, and X. Zhuang. 2013. Super-resolution fluorescence imaging of telomeres reveals TRF2-dependent T-loop formation. Cell. 155:345-356. http://dx.doi.org/10.1016/j.cell.2013.09.048
45. Else, T., A. Trovato, A.C. Kim, Y. Wu, D.O. Ferguson, R.D. Kuick, P.C. Lucas, and G.D. Hammer. 2009. Genetic p53 deficiency partially rescues the adrenocortical dysplasia phenotype at the expense of increased tumorigenesis. Cancer Cell. 15:465-476. http://dx.doi.org/10.1016/j.ccr.2009.04.011
46. Ferrón, S., H. Mira, S. Franco, M. Cano-Jaimez, E. Bellmunt, C. Ramírez, I. Fariñas, and M.A. Blasco. 2004. Telomere shortening and chromosomal instability abrogates proliferation of adult but not embryonic neural stem cells. Development. 131:4059-4070. http://dx.doi.org/10.1242/dev.01215
47. Flores, I., M.L. Cayuela, and M.A. Blasco. 2005. Effects of telomerase and telomere length on epidermal stem cell behavior. Science. 309:1253-1256. http://dx.doi.org/10.1126/science.1115025
48. Flores, I., A. Canela, E. Vera, A. Tejera, G. Cotsarelis, and M.A. Blasco. 2008. The longest telomeres: A general signature of adult stem cell compartments. Genes Dev. 22:654-667. http://dx.doi.org/10.1101/gad.451008
49. Fogarty, P.F., H. Yamaguchi, A. Wiestner, G.M. Baerlocher, E. Sloand, W.S. Zeng. E.J. Read, P.M. Lansdorp, and N.S. Young. 2003. Late presentation of dyskeratosis congenita as apparently acquired aplastic anaemia due to mutations in telomerase RNA. Lancet. 362:1628-1630
50. Fumagalli, M., F. Rossiello, M. Clerici, S. Barozzi, D. Cittaro, J.M. Kaplunov, G. Bucci, M. Dobreva, V. Matti, C.M. Beausejour, et al. 2012. Telomeric DNA damage is irreparable and causes persistent DNA-damage-response activation. Nat. Cell Biol. 14:355-365. http://dx.doi.org/10.1038/ncb2466
51. García-Beccaria, M., P. Martínez, M. Méndez-Pertuz, S. Martínez, C. Blanco-Aparicio, M. Cañamero, F. Mulero, C. Ambrogio, J.M. Flores, D. Megias, et al. 2015. Therapeutic inhibition of TRF1 impairs the growth of p53-deficient K-RasG12V-induced lung cancer by induction of telomeric DNA damage. EMBO Mol. Med. 7:930-949. http://dx.doi.org/10.15252/emmm.201404497
52. García-Cao, I., M. García-Cao, J. Martín-Caballero, L.M. Criado, P. Klatt, J.M. Flores, J.C. Weill, M.A. Blasco, and M. Serrano. 2002. "Super p53" mice exhibit enhanced DNA damage response, are tumor resistant and age normally. EMBO J. 21:6225-6235. http://dx.doi.org/10.1093/emboj/cdf595
53. George, G., I.O. Rosas, Y. Cui, C. McKane, G.M. Hunninghake, P.C. Camp, B.A. Raby, H.J. Goldberg, and S. El-Chemaly. 2015. Short telomeres, telomeropathy, and subclinical extrapulmonary organ damage in patients with interstitial lung disease. Chest. 147:1549-1557. http://dx.doi.org/10.1378/chest.14-0631
54. Glousker, G., F. Touzot, P. Revy, Y. Tzfati, and S.A. Savage. 2015. Unraveling the pathogenesis of Hoyeraal-Hreidarsson syndrome, a complex telomere biology disorder. Br. J. Haematol. 170:457-471. http://dx.doi.org/10.1111/bjh.13442
55. González-Suárez, E., E. Samper, J.M. Flores, and M.A. Blasco. 2000. Telomerase-deficient mice with short telomeres are resistant to skin tumorigenesis. Nat. Genet. 26:114-117. http://dx.doi.org/10.1038/79089
56. Greenberg, R.A., L. Chin, A. Femino, K.H. Lee, G.J. Gottlieb, R.H. Singer, C.W. Greider, and R.A. DePinho. 1999. Short dysfunctional telomeres impair tumorigenesis in the INK4a(delta2/3) cancer-prone mouse. Cell. 97:515-525. http://dx.doi.org/10.1016/S0092-8674(00)80761-8
57. Greider, C.W., and E.H. Blackburn. 1985. Identification of a specific telomere terminal transferase activity in Tetrahymena extracts. Cell. 43:405-413. http://dx.doi.org/10.1016/0092-8674(85)90170-9
58. Griffith, J.D., L. Comeau, S. Rosenfield, R.M. Stansel, A. Bianchi, H. Moss, and T. de Lange. 1999. Mammalian telomeres end in a large duplex loop. Cell. 97:503-514. http://dx.doi.org/10.1016/S0092-8674(00)80760-6
59. Harley, C.B. 2008. Telomerase and cancer therapeutics. Nat. Rev. Cancer. 8:167-179. http://dx.doi.org/10.1038/nrc2275
60. Harley, C.B., A.B. Futcher, and C.W. Greider. 1990. Telomeres shorten during ageing of human fibroblasts. Nature. 345:458-460. http://dx.doi.org/10.1038/345458a0
61. Harley, C.B., W. Liu, P.L. Flom, and J.M. Raffaele. 2013. A natural product telomerase activator as part of a health maintenance program: Metabolic and cardiovascular response. Rejuvenation Res. 16:386-395. http://dx.doi.org/10.1089/rej.2013.1430
62. Hastie, N.D., M. Dempster, M.G. Dunlop, A.M. Thompson, D.K. Green, and R.C. Allshire. 1990. Telomere reduction in human colorectal carcinoma and with ageing. Nature. 346:866-868. http://dx.doi.org/10.1038/346866a0
63. Hayashi, M.T., A.J. Cesare, J.A. Fitzpatrick, E. Lazzerini-Denchi, and J. Karlseder. 2012. A telomere-dependent DNA damage checkpoint induced by prolonged mitotic arrest. Nat. Struct. Mol. Biol. 19:387-394. http://dx.doi.org/10.1038/nsmb.2245
64. Hayashi, M.T., A.J. Cesare, T. Rivera, and J. Karlseder. 2015. Cell death during crisis is mediated by mitotic telomere deprotection. Nature. 522:492-496. http://dx.doi.org/10.1038/nature14513
65. He, H., Y. Wang, X. Guo, S. Ramchandani, J. Ma, M.F. Shen, D.A. Garcia, Y. Deng, A.S. Multani, M.J. You, and S. Chang. 2009. Pot1b deletion and telomerase haploinsufficiency in mice initiate an ATR-dependent DNA damage response and elicit phenotypes resembling dyskeratosis congenita. Mol. Cell. Biol. 29:229-240. http://dx.doi.org/10.1128/MCB.01400-08
66. Herrera, E., E. Samper, J. Martín-Caballero, J.M. Flores, H.W. Lee, and M.A. Blasco. 1999. Disease states associated with telomerase deficiency appear earlier in mice with short telomeres. EMBO J. 18:2950-2960. http://dx.doi.org/10.1093/emboj/18.11.2950
67. Hockemeyer, D., W. Palm, R.C. Wang, S.S. Couto, and T. de Lange. 2008. Engineered telomere degradation models dyskeratosis congenita. Genes Dev. 22:1773-1785. http://dx.doi.org/10.1101/gad.1679208
68. Hoffman, T.W., J.J. van der Vis, M.F. van Oosterhout, H.W. van Es, D.A. van Kessel, J.C. Grutters, and C.H. van Moorsel. 2016. TINF2 gene mutation in a patient with pulmonary fibrosis. Case Rep. Pulmonol. 2016:1310862. http://dx.doi.org/10.1155/2016/1310862
69. Holohan, B., W.E. Wright, and J.W. Shay. 2014. Telomeropathies: An emerging spectrum disorder. J. Cell Biol. 205:289-299. http://dx.doi.org/10.1083/jcb.201401012
70. Huang, D.S., Z. Wang, X.J. He, B.H. Diplas, R. Yang, P.J. Killela, Q. Meng, Z.Y. Ye, W. Wang, X.T. Jiang, et al. 2015. Recurrent TERT promoter mutations identified in a large-scale study of multiple tumour types are associated with increased TERT expression and telomerase activation. Eur. J. Cancer. 51:969-976. http://dx.doi.org/10.1016/j.ejca.2015.03.010
71. Hurst, C.D., F.M. Platt, and M.A. Knowles. 2014. Comprehensive mutation analysis of the TERT promoter in bladder cancer and detection of mutations in voided urine. Eur. Urol. 65:367-369. http://dx.doi.org/10.1016/j.eururo.2013.08.057
72. Jafri, M.A., S.A. Ansari, M.H. Alqahtani, and J.W. Shay. 2016. Roles of telomeres and telomerase in cancer, and advances in telomerase-targeted therapies. Genome Med. 8:69. http://dx.doi.org/10.1186/s13073-016-0324-x
73. Jaime-Pérez, J.C., P.R. Colunga-Pedraza, C.D. Gómez-Ramírez, C.H. Gutiérrez-Aguirre, O.G. Cantú-Rodríguez, L.C. Tarín-Arzaga, and D. Gómez-Almaguer. 2011. Danazol as first-line therapy for aplastic anemia. Ann. Hematol. 90:523-527. http://dx.doi.org/10.1007/s00277-011-1163-x
74. Kannengiesser, C., R. Borie, C. Ménard, M. Réocreux, P. Nitschké, S. Gazal, H. Mal, C. Taillé, J. Cadranel, H. Nunes, et al. 2015. Heterozygous RTEL1 mutations are associated with familial pulmonary fibrosis. Eur. Respir. J. 46:474-485. http://dx.doi.org/10.1183/09031936.00040115
75. Karlseder, J., D. Broccoli, Y. Dai, S. Hardy, and T. de Lange. 1999. p53-and ATM-dependent apoptosis induced by telomeres lacking TRF2. Science. 283:1321-1325. http://dx.doi.org/10.1126/science.283.5406.1321
76. Kaul, Z., A.J. Cesare, L.I. Huschtscha, A.A. Neumann, and R.R. Reddel. 2011. Five dysfunctional telomeres predict onset of senescence in human cells. EMBO Rep. 13:52-59. http://dx.doi.org/10.1038/embor.2011.227
77. Khoo, C.M., D.R. Carrasco, M.W. Bosenberg, J.H. Paik, and R.A. Depinho. 2007. Ink4a/Arf tumor suppressor does not modulate the degenerative conditions or tumor spectrum of the telomerase-deficient mouse. Proc. Natl. Acad. Sci. USA. 104:3931-3936. http://dx.doi.org/10.1073/pnas.0700093104
78. Kim, N.W., M.A. Piatyszek, K.R. Prowse, C.B. Harley, M.D. West, P.L. Ho, G.M. Coviello, W.E. Wright, S.L. Weinrich, and J.W. Shay. 1994. Specific association of human telomerase activity with immortal cells and cancer. Science. 266:2011-2015. http://dx.doi.org/10.1126/science.7605428
79. Kinde, I., E. Munari, S.F. Faraj, R.H. Hruban, M. Schoenberg, T. Bivalacqua, M. Allaf, S. Springer, Y. Wang, L.A. Diaz Jr., et al. 2013. TERT promoter mutations occur early in urothelial neoplasia and are biomarkers of early disease and disease recurrence in urine. Cancer Res. 73:7162-7167. http://dx.doi.org/10.1158/0008-5472.CAN-13-2498
80. Lee, H.W., M.A. Blasco, G.J. Gottlieb, J.W. Horner II, C.W. Greider, and R.A. DePinho. 1998. Essential role of mouse telomerase in highly proliferative organs. Nature. 392:569-574. http://dx.doi.org/10.1038/33345
81. Leri, A., S. Franco, A. Zacheo, L. Barlucchi, S. Chimenti, F. Limana, B. Nadal-Ginard, J. Kajstura, P. Anversa, and M.A. Blasco. 2003. Ablation of telomerase and telomere loss leads to cardiac dilatation and heart failure associated with p53 upregulation. EMBO J. 22:131-139. http://dx.doi.org/10.1093/emboj/cdg013
82. Levine, B., and G. Kroemer. 2008. Autophagy in the pathogenesis of disease. Cell. 132:27-42. http://dx.doi.org/10.1016/j.cell.2007.12.018
83. Lin, T.T., B.T. Letsolo, R.E. Jones, J. Rowson, G. Pratt, S. Hewamana, C. Fegan, C. Pepper, and D.M. Baird. 2010. Telomere dysfunction and fusion during the progression of chronic lymphocytic leukemia: Evidence for a telomere crisis. Blood. 116:1899-1907. http://dx.doi.org/10.1182/blood-2010-02-272104
84. Lindsey, J., N.I. McGill, L.A. Lindsey, D.K. Green, and H.J. Cooke. 1991. In vivo loss of telomeric repeats with age in humans. Mutat. Res. 256:45-48. http://dx.doi.org/10.1016/0921-8734(91)90032-7
85. Liu, D., A. Safari, M.S. O'Connor, D.W. Chan, A. Laegeler, J. Qin, and Z. Songyang. 2004. PTOP interacts with POT1 and regulates its localization to telomeres. Nat. Cell Biol. 6:673-680. http://dx.doi.org/10.1038/ncb1142
86. Liu, L., S.M. Bailey, M. Okuka, P. Muñoz, C. Li, L. Zhou, C. Wu, E. Czerwiec, L. Sandler, A. Seyfang, et al. 2007. Telomere lengthening early in development. Nat. Cell Biol. 9:1436-1441. http://dx.doi.org/10.1038/ncb1664
87. López-Otín, C., M.A. Blasco, L. Partridge, M. Serrano, and G. Kroemer. 2013. The hallmarks of aging. Cell. 153:1194-1217. http://dx.doi.org/10.1016/j.cell.2013.05.039
88. Maciejowski, J., Y. Li, N. Bosco, P.J. Campbell, and T. de Lange. 2015. Chromothripsis and kataegis induced by telomere crisis. Cell. 163:1641-1654. http://dx.doi.org/10.1016/j.cell.2015.11.054
89. Marion, R.M., K. Strati, H. Li, A. Tejera, S. Schoeftner, S. Ortega, M. Serrano, and M.A. Blasco. 2009. Telomeres acquire embryonic stem cell characteristics in induced pluripotent stem cells. Cell Stem Cell. 4:141-154. http://dx.doi.org/10.1016/j.stem.2008.12.010
90. Martinez, P., I. Siegl-Cachedenier, J.M. Flores, and M.A. Blasco. 2009. MSH2 deficiency abolishes the anticancer and pro-aging activity of short telomeres. Aging Cell. 8:2-17. http://dx.doi.org/10.1111/j.1474-9726.2008.00441.x
91. Martinez, P., M. Thanasoula, A.R. Carlos, G. Gómez-López, A.M. Tejera, S. Schoeftner, O. Dominguez, D.G. Pisano, M. Tarsounas, and M.A. Blasco. 2010. Mammalian Rap1 controls telomere function and gene expression through binding to telomeric and extratelomeric sites. Nat. Cell Biol. 12:768-780. http://dx.doi.org/10.1038/ncb2081
92. Martínez, P., and M.A. Blasco. 2010. Role of shelterin in cancer and aging. Aging Cell. 9:653-666. http://dx.doi.org/10.1111/j.1474-9726.2010.00596.x
93. Martínez, P., and M.A. Blasco. 2011. Telomeric and extra-telomeric roles for telomerase and the telomere-binding proteins. Nat. Rev. Cancer. 11:161-176. http://dx.doi.org/10.1038/nrc3025
94. Martínez, P., M. Thanasoula, P. Muñoz, C. Liao, A. Tejera, C. McNees, J.M. Flores, O. Fernández-Capetillo, M. Tarsounas, and M.A. Blasco. 2009. Increased telomere fragility and fusions resulting from TRF1 deficiency lead to degenerative pathologies and increased cancer in mice. Genes Dev. 23:2060-2075. http://dx.doi.org/10.1101/gad.543509
95. Martínez, P., G. Gómez-López, D.G. Pisano, J.M. Flores, and M.A. Blasco. 2016. A genetic interaction between RAP1 and telomerase reveals an unanticipated role for RAP1 in telomere maintenance. Aging Cell. 15:1113-1125. http://dx.doi.org/10.1111/acel.12517
96. Meeker, A.K., J.L. Hicks, C.A. Iacobuzio-Donahue, E.A. Montgomery, W.H. Westra, T.Y. Chan, B.M. Ronnett, and A.M. De Marzo. 2004. Telomere length abnormalities occur early in the initiation of epithelial carcinogenesis. Clin. Cancer Res. 10:3317-3326. http://dx.doi.org/10.1158/1078-0432.CCR-0984-03
97. Mender, I., S. Gryaznov, Z.G. Dikmen, W.E. Wright, and J.W. Shay. 2015. Induction of telomere dysfunction mediated by the telomerase substrate precursor 6-thio-2'-deoxyguanosine. Cancer Discov. 5:82-95. http://dx.doi.org/10.1158/2159-8290.CD-14-0609
98. Miyachi, K., M. Fujita, N. Tanaka, K. Sasaki, and M. Sunagawa. 2002. Correlation between telomerase activity and telomeric-repeat binding factors in gastric cancer. J. Exp. Clin. Cancer Res. 21:269-275
99. Nakanishi, K., T. Kawai, F. Kumaki, S. Hiroi, M. Mukai, E. Ikeda, C.E. Koering, and E. Gilson. 2003. Expression of mRNAs for telomeric repeat binding factor (TRF)-1 and TRF2 in atypical adenomatous hyperplasia and adenocarcinoma of the lung. Clin. Cancer Res. 9:1105-1111
100. Newey, P.J., M.A. Nesbit, A.J. Rimmer, M. Attar, R.T. Head, P.T. Christie, C.M. Gorvin, M. Stechman, L. Gregory, R. Mihai, et al. 2012. Wholeexome sequencing studies of nonhereditary (sporadic) parathyroid adenomas. J. Clin. Endocrinol. Metab. 97:E1995-E2005. http://dx.doi.org/10.1210/jc.2012-2303
101. Olovnikov, A.M. 1973. A theory of marginotomy. The incomplete copying of template margin in enzymic synthesis of polynucleotides and biological significance of the phenomenon. J. Theor. Biol. 41:181-190. http://dx.doi.org/10.1016/0022-5193(73)90198-7
102. Pal, D., U. Sharma, S.K. Singh, N. Kakkar, and R. Prasad. 2015. Over-expression of telomere binding factors (TRF1 & TRF2) in renal cell carcinoma and their inhibition by using SiRNA induce apoptosis, reduce cell proliferation and migration invitro. PLoS One. 10:e0115651. http://dx.doi.org/10.1371/journal.pone.0115651
103. Palm, W., and T. de Lange. 2008. How shelterin protects mammalian telomeres. Annu. Rev. Genet. 42:301-334. http://dx.doi.org/10.1146/annurev.genet.41.110306.130350
104. Perera, S.A., R.S. Maser, H. Xia, K. McNamara, A. Protopopov, L. Chen, A.F. Hezel, C.F. Kim, R.T. Bronson, D.H. Castrillon, et al. 2008. Telomere dysfunction promotes genome instability and metastatic potential in a K-ras p53 mouse model of lung cancer. Carcinogenesis. 29:747-753. http://dx.doi.org/10.1093/carcin/bgn050
105. Pickett, H.A., and R.R. Reddel. 2015. Molecular mechanisms of activity and derepression of alternative lengthening of telomeres. Nat. Struct. Mol. Biol. 22:875-880. http://dx.doi.org/10.1038/nsmb.3106
106. Pinzaru, A.M., R.A. Hom, A. Beal, A.F. Phillips, E. Ni, T. Cardozo, N. Nair, J. Choi, D.S. Wuttke, A. Sfeir, and E.L. Denchi. 2016. Telomere replication stress induced by POT1 inactivation accelerates tumorigenesis. Cell Reports. 15:2170-2184. http://dx.doi.org/10.1016/j.celrep.2016.05.008
107. Povedano, J.M., P. Martinez, J.M. Flores, F. Mulero, and M.A. Blasco. 2015. Mice with pulmonary fibrosis driven by telomere dysfunction. Cell Reports. 12:286-299. http://dx.doi.org/10.1016/j.celrep.2015.06.028
108. Ramsay, A.J., V. Quesada, M. Foronda, L. Conde, A. Martínez-Trillos, N. Villamor, D. Rodríguez, A. Kwarciak, C. Garabaya, M. Gallardo, et al. 2013. POT1 mutations cause telomere dysfunction in chronic lymphocytic leukemia. Nat. Genet. 45:526-530. http://dx.doi.org/10.1038/ng.2584
109. Ramunas, J., E. Yakubov, J.J. Brady, S.Y. Corbel, C. Holbrook, M. Brandt, J. Stein, J.G. Santiago, J.P. Cooke, and H.M. Blau. 2015. Transient delivery of modified mRNA encoding TERT rapidly extends telomeres in human cells. FAS EB J. 29:1930-1939. http://dx.doi.org/10.1096/fj.14-259531
110. Robin, J.D., A.T. Ludlow, K. Batten, F. Magdinier, G. Stadler, K.R. Wagner, J.W. Shay, and W.E. Wright. 2014. Telomere position effect: Regulation of gene expression with progressive telomere shortening over long distances. Genes Dev. 28:2464-2476. http://dx.doi.org/10.1101/gad.251041.114
111. Robles-Espinoza, C.D., M. Harland, A.J. Ramsay, L.G. Aoude, V. Quesada, Z. Ding, K.A. Pooley, A.L. Pritchard, J.C. Tiffen, M. Petljak, et al. 2014. POT1 loss-of-function variants predispose to familial melanoma. Nat. Genet. 46:478-481. http://dx.doi.org/10.1038/ng.2947
112. Roger, L., R.E. Jones, N.H. Heppel, G.T. Williams, J.R. Sampson, and D.M. Baird. 2013. Extensive telomere erosion in the initiation of colorectal adenomas and its association with chromosomal instability. J. Natl. Cancer Inst. 105:1202-1211. http://dx.doi.org/10.1093/jnci/djt191
113. Saito, K., A. Yagihashi, S. Nasu, Y. Izawa, M. Nakamura, D. Kobayashi, N. Tsuji, and N. Watanabe. 2002. Gene expression for suppressors of telomerase activity (telomeric-repeat binding factors) in breast cancer. Jpn. J. Cancer Res. 93:253-258. http://dx.doi.org/10.1111/j.1349-7006.2002.tb02166.x
114. Sanders, J.L., and A.B. Newman. 2013. Telomere length in epidemiology: A biomarker of aging, age-related disease, both, or neither? Epidemiol. Rev. 35:112-131. http://dx.doi.org/10.1093/epirev/mxs008
115. Savage, S.A., N. Giri, G.M. Baerlocher, N. Orr, P.M. Lansdorp, and B.P. Alter. 2008. TINF2, a component of the shelterin telomere protection complex, is mutated in dyskeratosis congenita. Am. J. Hum. Genet. 82:501-509. http://dx.doi.org/10.1016/j.ajhg.2007.10.004
116. Schneider, R.P., I. Garrobo, M. Foronda, J.A. Palacios, R.M. Marión, I. Flores, S. Ortega, and M.A. Blasco. 2013. TRF1 is a stem cell marker and is essential for the generation of induced pluripotent stem cells. Nat. Commun. 4:1946. http://dx.doi.org/10.1038/ncomms2946
117. Seger, Y.R., M. García-Cao, S. Piccinin, C.L. Cunsolo, C. Doglioni, M.A. Blasco, G.J. Hannon, and R. Maestro. 2002. Transformation of normal human cells in the absence of telomerase activation. Cancer Cell. 2:401-413. http://dx.doi.org/10.1016/S1535-6108(02)00183-6
118. Sfeir, A., S. Kabir, M. van Overbeek, G.B. Celli, and T. de Lange. 2010. Loss of Rap1 induces telomere recombination in the absence of NHEJ or a DNA damage signal. Science. 327:1657-1661. http://dx.doi.org/10.1126/science.1185100
119. Shahidi, N.T., and L.K. Diamond. 1961. Testosterone-induced remission in aplastic anemia of both acquired and congenital types. Further observations in 24 cases. N. Engl. J. Med. 264:953-967. http://dx.doi.org/10.1056/NEJM196105112641901
120. Sharpless, N.E., and R.A. DePinho. 2007. How stem cells age and why this makes us grow old. Nat. Rev. Mol. Cell Biol. 8:703-713. http://dx.doi.org/10.1038/nrm2241
121. Shay, J.W. 2016. Role of telomeres and telomerase in aging and cancer. Cancer Discov. 6:584-593. http://dx.doi.org/10.1158/2159-8290.CD-16-0062
122. Shay, J.W., and W.E. Wright. 2005. Senescence and immortalization: Role of telomeres and telomerase. Carcinogenesis. 26:867-874. http://dx.doi.org/10.1093/carcin/bgh296
123. Shi, J., X.R. Yang, B. Ballew, M. Rotunno, D. Calista, M.C. Fargnoli, P. Ghiorzo, B. Bressac-de Paillerets, E. Nagore, M.F. Avril, et al. French Familial Melanoma Study Group. 2014. Rare missense variants in POT1 predispose to familial cutaneous malignant melanoma. Nat. Genet. 46:482-486. http://dx.doi.org/10.1038/ng.2941
124. Shih, I.M., W. Zhou, S.N. Goodman, C. Lengauer, K.W. Kinzler, and B. Vogelstein. 2001. Evidence that genetic instability occurs at an early stage of colorectal tumorigenesis. Cancer Res. 61:818-822
125. Simeonova, I., S. Jaber, I. Draskovic, B. Bardot, M. Fang, R. Bouarich-Bourimi, V. Lejour, L. Charbonnier, C. Soudais, J.C. Bourdon, et al. 2013. Mutant mice lacking the p53 C-terminal domain model telomere syndromes. Cell Reports. 3:2046-2058. http://dx.doi.org/10.1016/j.celrep.2013.05.028
126. Stadler, G., F. Rahimov, O.D. King, J.C. Chen, J.D. Robin, K.R. Wagner, J.W. Shay, C.P. Emerson Jr., and W.E. Wright. 2013. Telomere position effect regulates DUX4 in human facioscapulohumeral muscular dystrophy. Nat. Struct. Mol. Biol. 20:671-678. http://dx.doi.org/10.1038/nsmb.2571
127. Stanley, S.E., and M. Armanios. 2015. The short and long telomere syndromes: Paired paradigms for molecular medicine. Curr. Opin. Genet. Dev. 33:1-9. http://dx.doi.org/10.1016/j.gde.2015.06.004
128. Stanley, S.E., D.L. Gable, C.L. Wagner, T.M. Carlile, V.S. Hanumanthu, J.D. Podlevsky, S.E. Khalil, A.E. DeZern, M.F. Rojas-Duran, C.D. Applegate, et al. 2016. Loss-of-function mutations in the RNA biogenesis factor NAF1 predispose to pulmonary fibrosis-emphysema. Sci. Transl. Med. 8:351ra107. http://dx.doi.org/10.1126/scitranslmed.aaf7837
129. Stuart, B.D., J. Choi, S. Zaidi, C. Xing, B. Holohan, R. Chen, M. Choi, P. Dharwadkar, F. Torres, C.E. Girod, et al. 2015. Exome sequencing links mutations in PARN and RTEL1 with familial pulmonary fibrosis and telomere shortening. Nat. Genet. 47:512-517. http://dx.doi.org/10.1038/ng.3278
130. Tchkonia, T., Y. Zhu, J. van Deursen, J. Campisi, and J.L. Kirkland. 2013. Cellular senescence and the senescent secretory phenotype: Therapeutic opportunities. J. Clin. Invest. 123:966-972. http://dx.doi.org/10.1172/JCI64098
131. Tefferi, A., T.L. Lasho, K.H. Begna, M.M. Patnaik, D.L. Zblewski, C.M. Finke, R.R. Laborde, E. Wassie, L. Schimek, C.A. Hanson, et al. 2015. A pilot study of the telomerase inhibitor imetelstat for myelofibrosis. N. Engl. J. Med. 373:908-919. http://dx.doi.org/10.1056/NEJMoa1310523
132. Tejera, A.M., M. Stagno d'Alcontres, M. Thanasoula, R.M. Marion, P. Martinez, C. Liao, J.M. Flores, M. Tarsounas, and M.A. Blasco. 2010. TPP1 is required for TERT recruitment, telomere elongation during nuclear reprogramming, and normal skin development in mice. Dev. Cell. 18:775-789. http://dx.doi.org/10.1016/j.devcel.2010.03.011
133. Tomás-Loba, A., I. Flores, P.J. Fernández-Marcos, M.L. Cayuela, A. Maraver, A. Tejera, C. Borrás, A. Matheu, P. Klatt, J.M. Flores, et al. 2008. Telomerase reverse transcriptase delays aging in cancer-resistant mice. Cell. 135:609-622. http://dx.doi.org/10.1016/j.cell.2008.09.034
134. Townsley, D.M., B. Dumitriu, D. Liu, A. Biancotto, B. Weinstein, C. Chen, N. Hardy, A.D. Mihalek, S. Lingala, Y.J. Kim, et al. 2016. Danazol treatment for telomere diseases. N. Engl. J. Med. 374:1922-1931. http://dx.doi.org/10.1056/NEJMoa1515319
135. Varela, E., R.P. Schneider, S. Ortega, and M.A. Blasco. 2011. Different telomerelength dynamics at the inner cell mass versus established embryonic stem (ES) cells. Proc. Natl. Acad. Sci. USA. 108:15207-15212. http://dx.doi.org/10.1073/pnas.1105414108
136. Varela, E., M.A. Muñoz-Lorente, A.M. Tejera, S. Ortega, and M.A. Blasco. 2016. Generation of mice with longer and better preserved telomeres in the absence of genetic manipulations. Nat. Commun. 7:11739. http://dx.doi.org/10.1038/ncomms11739
137. Vera, E., B. Bernardes de Jesus, M. Foronda, J.M. Flores, and M.A. Blasco. 2012. The rate of increase of short telomeres predicts longevity in mammals. Cell Reports. 2:732-737. http://dx.doi.org/10.1016/j.celrep.2012.08.023
138. Vitale, I., L. Galluzzi, M. Castedo, and G. Kroemer. 2011. Mitotic catastrophe: A mechanism for avoiding genomic instability. Nat. Rev. Mol. Cell Biol. 12:385-392. http://dx.doi.org/10.1038/nrm3115
139. Wang, E.S., K. Wu, A.C. Chin, S. Chen-Kiang, K. Pongracz, S. Gryaznov, and M.A. Moore. 2004. Telomerase inhibition with an oligonucleotide telomerase template antagonist: In vitro and in vivo studies in multiple myeloma and lymphoma. Blood. 103:258-266. http://dx.doi.org/10.1182/blood-2003-02-0546
140. Watson, J.D. 1972. Origin of concatemeric T7 DNA. Nat. New Biol. 239:197-201. http://dx.doi.org/10.1038/newbio239197a0
141. Wright, W.E., and J.W. Shay. 1992. The two-stage mechanism controlling cellular senescence and immortalization. Exp. Gerontol. 27:383-389. http://dx.doi.org/10.1016/0531-5565(92)90069-C
142. Zhang, J., D. Jima, A.B. Moffitt, Q. Liu, M. Czader, E.D. Hsi, Y. Fedoriw, C.H. Dunphy, K.L. Richards, J.I. Gill, et al. 2014. The genomic landscape of mantle cell lymphoma is related to the epigenetically determined chromatin state of normal B cells. Blood. 123:2988-2996. http://dx.doi.org/10.1182/blood-2013-07-517177
143. Zou, Y., A. Sfeir, S.M. Gryaznov, J.W. Shay, and W.E. Wright. 2004. Does a sentinel or a subset of short telomeres determine replicative senescence? Mol. Biol. Cell. 15:3709-3718. http://dx.doi.org/10.1091/mbc.E04-03-0207